Please rotate your device.
Next Level Technology for Next Level Protection
NanoBio® Protect is developed by BlueWillow, a vaccine research company led by a team of cutting-edge doctors and scientists:
Dr. Costley is a primary care physician with over 20 years of medical and entrepreneurial experience. Before taking the helm of BlueWillow in July 2020, Dr. Costley held positions on BlueWillow’s board of directors and as CMO.
Dr. Fattom joined BlueWillow Biologics with over 25 years of experience in vaccine research and development. His previous work includes conjugate vaccines for S. aureus and Pneumococcus.
Dr. Ganesan has over 16 years of combined academic and industrial experience in immunology and microbiology. She is involved in the development of nanoemulsion adjuvanted vaccines against infectious diseases and peanut allergy.
BlueWillow Biologics® is a clinical-stage, privately-held biopharmaceutical company focused on developing topical antiseptics, anti-infective products, and intranasal vaccines using its patented nanotechnology platform. The platform employs novel oil-in-water nanodroplets for products administered to the skin and nose.
The company was founded as a spin-off from the University of Michigan, and was initially focused on developing nano-scale dermatology applications. Based on promising research generated under several Gates Foundation, NIH and DOD contracts, BlueWillow’s technology has advanced significantly in recent years, yielding several therapies in development, including NanoBio Protect.
BlueWillow’s lead NanoBio Protect product is an alcohol-free, nasal antiseptic that has been shown to kill 99.99% of germs in lab tests. The FDA Over-the-Counter (OTC) product is applied by thoroughly swabbing the skin inside of each nostril and is recommended for use to help reduce germs on the skin that can cause infection. NanoBio Protect is non-irritating, fragrance-free and leaves no residue after application. Other topical NanoBio products are currently being developed for wounds and other skin ailments.
In parallel, BlueWillow Biologics is developing its proprietary NanoVax® platform to enable intranasal vaccines for challenging respiratory & sexually transmitted infections and intranasal immunotherapy (INIT) for food & respiratory allergies. The company’s lead candidates include intranasal vaccines for influenza, anthrax, RSV and HSV-2, and intranasal immunotherapy for peanut and milk allergy. The company’s NanoVax technology platform utilizes a novel oil-in-water emulsion adjuvant to enable intranasal vaccines and immunotherapy that elicit mucosal and systemic Th1/Th17 immunity. The NanoVax platform uniquely elicits mucosal antibodies that serve as “bouncers at the door” — the body’s first line of defense against infections and allergens.
To date, over $190 million has been invested in developing BlueWillow’s nanotechnology platform. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.